Expert Shares Experience With Amivantamab/Lazertinib

Recent clinical experience with amivantamab, particularly in combination regimens like those studied in MARIPOSA, highlights its effectiveness and manageability when paired with proper patient education and proactive adverse effect management. Initially used in the relapsed/refractory setting and later for patients with EGFR exon 20 insertions, the drug has shown significant improvement in outcomes. More recent use in frontline settings confirms that, with the right supportive strategies, patients can remain on therapy with minimal dose reductions. Prophylactic skin care and patient education have played a key role in enabling sustained treatment.

A critical aspect of successful management is setting expectations early. Educating patients about the type of adverse effects they may encounter—especially rash and skin-related issues associated with EGFR inhibition—is essential. Simply telling patients that adverse effects may occur is not sufficient; they need clear guidance on what to look for and when to reach out. Reinforcing these messages through nursing support, including instruction on sun protection and skin/nail care routines, ensures better adherence and engagement. This team-based, proactive approach has led to improved patient outcomes and fewer treatment interruptions.

Overall, the ability to keep patients on amivantamab-based therapies long-term—sometimes for years—speaks to the manageability of the regimen when adverse effects are addressed head-on. Although adverse effects are real and require attention, they are typically manageable with early intervention. Tailoring care to individual patient needs, emphasizing preventive strategies, and maintaining open communication throughout treatment can allow patients to fully benefit from the therapeutic gains seen in trials like MARIPOSA. This reflects a broader trend in oncology toward not just effective therapies, but sustainable, patient-centered cancer care.